The field of neuromodulation has never been hotter. At the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas in December, attendance was at an all-time high, and the increasing number of clinical trials, new products and potential clinical applications for neuromodulation devices is a testament to the growing interest and excitement about these technologies among clinicians, industry, investors and patients.
Much of the research and news at NANS surrounded the latest advances in spinal cord stimulation (SCS) and today, traditional SCS comprises more than 50% of the $3.2 billion global...